Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 8;6(4):MMT30.
doi: 10.2217/mmt-2019-0005.

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management

Ester Simeone  1 , Antonio M Grimaldi  1 , Lucia Festino  1 , Claudia Trojaniello  1 , Maria G Vitale  1 , Vito Vanella  1 , Marco Palla  1 , Paolo A Ascierto  1
Affiliations
Review

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management

Ester Simeone et al. Melanoma Manag. .

Abstract

Checkpoint inhibitors can cause an imbalance in immune tolerance that may clinically manifest as immune-related adverse events (irAEs). These events may involve many organs and tissues, including the skin, gastrointestinal (GI) tract, liver, endocrine system, kidneys, central nervous system (CNS), eyes and lungs. The incidence of irAEs appears to be lower with anti-programmed death antigen-1/programmed death antigen-ligand-1 agents than with the anti-cytotoxic T-lymphocyte-associated protein-4 antibody ipilimumab. Combined immunotherapy does not appear to be associated with novel safety signals compared with monotherapy, but more organs may be involved. Increased experience and the use of algorithms for the most common irAEs have resulted in severe toxicity and related deaths being reduced. However, continuous vigilance, especially regarding less common events, is needed to better characterize the wide spectrum of clinical manifestations.

Keywords: anti-CTLA-4; anti-PD1; checkpoint inhibitors; combination therapy; immune-related adverse events.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Comment in

References

    1. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am. Soc. Clin. Oncol. Educ. Book 35(76), 76–83 (2015). - PubMed

    2. • Two papers of Weber et al. and Postow et al. that give exhaustive information on immune-related adverse events (irAEs) management in clinical practice.

    1. Weber JS, Yang JC, Aktins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33(18), 2092–2099 (2015). - PMC - PubMed

    2. • Two papers of Weber et al. and Postow et al. that give exhaustive information on irAEs management in clinical practice.

    1. Good-Jacobson KL, Szumilas CG, Chen L. et al. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat. Immunol. 11(6), 535–542 (2010). - PMC - PubMed
    1. Iwama S, De Remigis A, Callahan MK. et al. Pitiutary expression of CTLA-4 blocking antibody. Sci. Transl. Med. 6(230), 230–245 (2014). - PubMed
    1. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1(8), 1223–1225 (2012). - PMC - PubMed

LinkOut - more resources